CLDX vs LNTH
Celldex Therapeutics, Inc. and Lantheus Holdings, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CLDX | LNTH |
|---|---|---|
| Revenue | $1.5M | $1.5B |
| Net income | $-258.8M | $233.6M |
| Gross margin | 87.1% | 61.1% |
| Net margin | · | 15.2% |
| Return on equity | −40.6% | 21.4% |
| Diluted EPS | −$3.90 | $3.41 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-213.7M | · |
| Equity | $527.2M | $1.1B |
| Net debt / equity | · | 0.19× |
| Current ratio | 10.49× | 2.70× |
| Revenue CAGR 5y | −26.9% | 35.3% |
| Profit CAGR 5y | · | · |
LNTH bills 997.8× the revenue of CLDX, and CLDX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | CLDX | LNTH |
|---|---|---|
| FY2025 | $1.5M | $1.5B |
| FY2024 | $7.0M | $1.5B |
| FY2023 | $6.9M | $1.3B |
| FY2022 | $2.4M | $935.1M |
| FY2021 | $4.7M | $425.2M |
| FY2020 | $7.4M | $339.4M |
| FY2019 | $3.6M | $347.3M |
| FY2018 | $9.5M | $343.4M |
| FY2017 | $12.7M | $331.4M |
| FY2016 | $6.8M | $301.9M |
Bottom line
| Fiscal year | CLDX | LNTH |
|---|---|---|
| FY2025 | $-258.8M | $233.6M |
| FY2024 | $-157.9M | $312.4M |
| FY2023 | $-141.4M | $326.7M |
| FY2022 | $-112.3M | $28.1M |
| FY2021 | $-70.5M | $-71.3M |
| FY2020 | $-59.8M | $-13.5M |
| FY2019 | $-50.9M | $31.7M |
| FY2018 | $-151.2M | $40.5M |
| FY2017 | $-93.0M | $123.4M |
| FY2016 | $-128.5M | $26.8M |
13 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$1,540,064,000 | LNTH |
| FY2024 | −$1,526,890,000 | LNTH |
| FY2023 | −$1,289,546,000 | LNTH |
| FY2022 | −$932,704,000 | LNTH |
| FY2021 | −$420,557,000 | LNTH |
| FY2020 | −$331,992,000 | LNTH |
| FY2019 | −$343,764,000 | LNTH |
| FY2018 | −$333,836,000 | LNTH |
| FY2017 | −$318,635,000 | LNTH |
| FY2016 | −$295,067,000 | LNTH |
| FY2015 | −$287,981,000 | LNTH |
| FY2014 | −$298,014,000 | LNTH |
| FY2013 | −$279,561,000 | LNTH |
LNTH has reported the higher revenue in every one of these 13 fiscal years. The gap has widened since the earliest year compared.
13 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LNTH's return on equity has been more volatile than CLDX's over the 8 comparable fiscal years — 30.3 percentage points of standard deviation against 17.9.
8 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LNTH led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 17 comparable fiscal years — a year missing data on either side is not counted.